NCT01848457
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
See it on ClinicalTrials.gov ↗13 people
61.5%
38.5%
8 womenmiddle line = equal numbers5 men
- Phase
- PHASE2
- Paid for by
- Children's Hospital of Philadelphia
- Finished
- 2016-10-01
- Health conditions
- Osteosarcoma, Nephrotoxicity, Ototoxicity
- Who could join
- Anyone
- Ages
- no minimum – 30 Years
- Average age
- mean 11.4 years
- Age 65+
- 0%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 30 Years.”
- No pregnant women
Women who were pregnant could not join.
“Pregnant or breastfeeding”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnant or breastfeeding”
Study titles and rules are shown in their original English.